680 related articles for article (PubMed ID: 18826204)
21. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
[TBL] [Abstract][Full Text] [Related]
22. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
Das K; Lewi PJ; Hughes SH; Arnold E
Prog Biophys Mol Biol; 2005 Jun; 88(2):209-31. PubMed ID: 15572156
[TBL] [Abstract][Full Text] [Related]
23. Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Sweeney ZK; Dunn JP; Li Y; Heilek G; Dunten P; Elworthy TR; Han X; Harris SF; Hirschfeld DR; Hogg JH; Huber W; Kaiser AC; Kertesz DJ; Kim W; Mirzadegan T; Roepel MG; Saito YD; Silva TM; Swallow S; Tracy JL; Villasenor A; Vora H; Zhou AS; Klumpp K
Bioorg Med Chem Lett; 2008 Aug; 18(15):4352-4. PubMed ID: 18632268
[TBL] [Abstract][Full Text] [Related]
24. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Parrotta L; Perno CF; Svicher V
Drug Resist Updat; 2011 Jun; 14(3):141-9. PubMed ID: 21295512
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA
J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435
[TBL] [Abstract][Full Text] [Related]
26. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
Gomez R; Jolly S; Williams T; Tucker T; Tynebor R; Vacca J; McGaughey G; Lai MT; Felock P; Munshi V; DeStefano D; Touch S; Miller M; Yan Y; Sanchez R; Liang Y; Paton B; Wan BL; Anthony N
Bioorg Med Chem Lett; 2011 Dec; 21(24):7344-50. PubMed ID: 22071300
[TBL] [Abstract][Full Text] [Related]
28. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Domaoal RA; Demeter LM
Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
[TBL] [Abstract][Full Text] [Related]
29. Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
Butini S; Brindisi M; Cosconati S; Marinelli L; Borrelli G; Coccone SS; Ramunno A; Campiani G; Novellino E; Zanoli S; Samuele A; Giorgi G; Bergamini A; Di Mattia M; Lalli S; Galletti B; Gemma S; Maga G
J Med Chem; 2009 Feb; 52(4):1224-8. PubMed ID: 19170521
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Schenone S; Bruno O; Bondavalli F; Vargiu L; Marceddu T; Mura M; La Colla P; Pani A
J Med Chem; 2003 Feb; 46(5):768-81. PubMed ID: 12593657
[TBL] [Abstract][Full Text] [Related]
31. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
Himmel DM; Das K; Clark AD; Hughes SH; Benjahad A; Oumouch S; Guillemont J; Coupa S; Poncelet A; Csoka I; Meyer C; Andries K; Nguyen CH; Grierson DS; Arnold E
J Med Chem; 2005 Dec; 48(24):7582-91. PubMed ID: 16302798
[TBL] [Abstract][Full Text] [Related]
32. N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Mitchell ML; Son JC; Lee IY; Lee CK; Kim HS; Guo H; Wang J; Hayes J; Wang M; Paul A; Lansdon EB; Chen JM; Eisenberg G; Geleziunas R; Xu L; Kim CU
Bioorg Med Chem Lett; 2010 Mar; 20(5):1585-8. PubMed ID: 20137928
[TBL] [Abstract][Full Text] [Related]
33. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
34. Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
Kertesz DJ; Brotherton-Pleiss C; Yang M; Wang Z; Lin X; Qiu Z; Hirschfeld DR; Gleason S; Mirzadegan T; Dunten PW; Harris SF; Villaseñor AG; Hang JQ; Heilek GM; Klumpp K
Bioorg Med Chem Lett; 2010 Jul; 20(14):4215-8. PubMed ID: 20538456
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
Cullen MD; Deng BL; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; Clercq ED; Cushman M
J Med Chem; 2007 Oct; 50(20):4854-67. PubMed ID: 17803290
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Ma XD; Zhang X; Dai HF; Yang SQ; Yang LM; Gu SX; Zheng YT; He QQ; Chen FE
Bioorg Med Chem; 2011 Aug; 19(15):4601-7. PubMed ID: 21719299
[TBL] [Abstract][Full Text] [Related]
37. Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
Tang G; Kertesz DJ; Yang M; Lin X; Wang Z; Li W; Qiu Z; Chen J; Mei J; Chen L; Mirzadegan T; Harris SF; Villaseñor AG; Fretland J; Fitch WL; Hang JQ; Heilek G; Klumpp K
Bioorg Med Chem Lett; 2010 Oct; 20(20):6020-3. PubMed ID: 20829038
[TBL] [Abstract][Full Text] [Related]
38. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Ren J; Stammers DK
Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
Ribone SR; Leen V; Madrid M; Dehaen W; Daelemans D; Pannecouque C; Briñón MC
Eur J Med Chem; 2012 Dec; 58():485-92. PubMed ID: 23159806
[TBL] [Abstract][Full Text] [Related]
40. The effect of NNRTIs on HIV reverse transcriptase dimerization.
Tachedjian G; Goff SP
Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
